The Leukemia & Lymphoma Society (LLS) funds new and innovative research that shows high promise for translating basic biomedical knowledge to clinical application. The goal of translational research is to reduce the time between laboratory findings and actual treatment.

Applications are sought proposing novel approaches to the prevention, diagnosis or treatment of leukemia, lymphoma and myeloma. Proposals should be based on molecular, cellular or integrated systems findings and be conceptually innovative. The application should have a clear plan for the clinical exploitation of the studies proposed and the results expected. This feature of the proposal will be an important consideration of the review process. While work directed at a further elucidation and understanding of the fundamental cellular and molecular biology of neoplastic lymphohematopoietic cells is a research priority of LLS, the Translational Research Program is specifically intended for the support of work which is clearly clinical in orientation. Applicants (Principal Investigator) must hold an M.D., Ph.D., or equivalent degree, and work in domestic or foreign non-profit organizations, such as universities, colleges, hospitals or laboratories. Applicants need not be U.S. citizens.

MAXIMUM OVERHEAD OF $19,982 OR 11.1 PERCENT OF DIRECT COSTS

RESEARCHPROGRAMS@LLS.ORG
1311 Mamaroneck Avenue, Suite 310
White Plains, New York, United States
914 949-5213